Eagle Pharmaceuticals (NASDAQ:EGRX) reported Q4 2017 earnings this Morning, coming in at ($0.79) per share, missing Wall Street’s estimates of $1.00 per Share. Revenue for the quarter came in at $46.80 million missing the streets estimates of $53.65 million Recent Insider Trading for Eagle Pharmaceuticals (NASDAQ:EGRX)
- On 8/16/2017 Pete A Meyers, CFO, bought 350 with an average share price of $55.45 per share and the total transaction amounting to $19,407.50.
- On 8/9/2017 Douglas L Braunstein, Director, bought 20,400 with an average share price of $49.07 per share and the total transaction amounting to $1,001,028.00.
- On 6/12/2017 Pete A Meyers, CFO, bought 350 with an average share price of $71.49 per share and the total transaction amounting to $25,021.50.
- On 5/19/2017 David Pernock, Insider, bought 255 with an average share price of $79.69 per share and the total transaction amounting to $20,320.95.
- On 5/16/2017 David Pernock, Insider, bought 200 with an average share price of $82.24 per share and the total transaction amounting to $16,448.00.
- On 4/25/2017 Proquest Investments Iv, L.P., Major Shareholder, sold 54,180 with an average share price of $88.38 per share and the total transaction amounting to $4,788,428.40.
Recent Trading for Eagle Pharmaceuticals (NASDAQ:EGRX) Shares of Eagle Pharmaceuticals closed the previous trading session at 58.22 down -8.64 12.92% with shares trading hands.